Mandal Gaurav, Lale Ajit, Greco Rick
Internal Medicine, Trinity Medical Center West, Steubenville, USA.
Cureus. 2022 Jun 22;14(6):e26200. doi: 10.7759/cureus.26200. eCollection 2022 Jun.
E-vape and e-cigarettes-associated lung injury (EVALI) is a diagnostic dilemma and even more obscure during the coronavirus disease 2019 (COVID-19) pandemic. A rise was seen in EVALI cases at the beginning of the COVID-19 pandemic. Still, the non-specific presentation, or the overlapping symptoms of COVID-19 and EVALI, can negate the possible diagnosis of EVALI because of a clinician's predisposition toward infectious etiologies, and it becomes even more challenging during a viral pandemic. The patient's social history remains the key distinctive point in diagnosing EVALI. Systemic steroids are generally used along with supportive care to treat patients with EVALI. This case report demonstrates the dilemma in diagnosing EVALI in a 19-year-old female during the COVID-19 pandemic.
电子烟及电子烟相关肺损伤（EVALI）是一种诊断难题，在2019冠状病毒病（COVID-19）大流行期间更加难以明确。在COVID-19大流行开始时，EVALI病例有所增加。然而，由于临床表现不具特异性，或COVID-19与EVALI症状重叠，加上临床医生倾向于认为病因是感染性的，可能会否定EVALI的诊断，而在病毒大流行期间这一情况更具挑战性。患者的社会史仍是诊断EVALI的关键区别点。系统性类固醇通常与支持性治疗一起用于治疗EVALI患者。本病例报告展示了在COVID-19大流行期间诊断一名19岁女性EVALI的困境。
